A photo of Michael J. Rosen.

Medical Director, Schubert-Martin Inflammatory Bowel Disease Center

Associate Director for Faculty Development, Division of Gastroenterology, Hepatology and Nutrition

Associate Professor, UC Department of Pediatrics

513-636-4415

Board Certified

My Biography & Research

Biography

I was inspired to pursue my career by my father, who is a physician, and my mother, who is a grade school teacher. They modeled for me the importance of caring for others and investing in our children. My personal experience with ulcerative colitis motivated me to care for children with inflammatory bowel disease (IBD).

As a pediatric gastroenterologist, I treat children and adolescents with digestive disorders. My focus is on IBD, including ulcerative colitis, Crohn’s disease and very early onset IBD. In my practice, personal connections are important to me. I hope to build a meaningful relationship with each patient and their family, where we work together to restore and maintain their health. When deciding on the best treatment course together, we consider both the most up-to-date medical evidence as well as each patient's individual needs and priorities.

At Cincinnati Children’s, we offer collaborative care. Our patients have access to a team of exceptional nurses, dietitians, social workers, psychologists, surgeons and other pediatric specialists with expertise in caring for children and young adults with IBD.

I’m the chairperson of the Crohn's and Colitis Foundation's PRO-KIIDS Pediatric IBD Research Network. This is a group of 30 pediatric IBD centers working together to develop better approaches to treating children and adolescents with IBD. I am also on the editorial board of the journal Inflammatory Bowel Diseases.

My research seeks to understand how the body's immune system interacts with the cells that line the intestine to maintain a healthy digestive tract. To do this, we are using models of the human intestine cultured in a dish called organoids or "mini-guts." We believe these "mini-guts" will teach us about what is going wrong in inflammatory bowel disease and allow us to use them to test new treatment approaches. My research is funded by the National Institutes of Health, and I have authored over 40 articles in major medical and scientific journals.

I enjoy spending my time away from work with my wife and two children. I love the movies, and I am an immense Star Wars fan.

Clinical Interests

Pediatric gastroenterology; pediatric inflammatory bowel disease

Research Interests

Mucosal immunology; epithelial biology; clinical pharmacology

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Divisions

Gastroenterology GI, Inflammatory Bowel Disease IBD, Autoimmune Liver Disease, Gastroenterology

My Locations

My Education

MD: Harvard Medical School, Boston, MA, 2003.

Residency: Boston Combined Residency Program in Pediatrics (Boston Children's Hospital and Boston Medical Center), Boston, MA, 2003-2006.

Fellowship: Pediatric Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center and the Monroe Carell, Jr. Children's Hospital at Vanderbilt, Nashville, TN, 2006-2009.

Masters of Science in Clinical Investigation (MSCI): Vanderbilt University School of Medicine, Nashville, TN, 2009.

Certification: Pediatrics, 2007; Pediatric Gastroenterology, Hepatology and Nutrition, 2009.

My Publications

Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Bauman, LE; Xiong, Y; Mizuno, T; Minar, P; Fukuda, T; Dong, M; Rosen, MJ; Vinks, AA. Inflammatory Bowel Diseases. 2020; 26:429-439.

Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Haberman, Y; Karns, R; Dexheimer, PJ; Schirmer, M; Somekh, J; Jurickova, I; Braun, T; Novak, E; Bauman, L; Collins, MH; et al. Nature Communications. 2019; 10.

Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Haberman, Y; Karns, R; Dexheimer, PJ; Schirmer, M; Somekh, J; Jurickova, I; Braun, T; Novak, E; Bauman, L; Collins, MH; et al. Nature Communications. 2019; 10.

Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab. Minar, P; Lehn, C; Tsai, Y; Jackson, K; Rosen, MJ; Denson, LA. Crohn's && Colitis 360. 2019; 1.

Development of Infliximab Target Concentrations during Induction in Pediatric Crohn Disease Patients. Clarkston, K; Tsai, Y; Jackson, K; Rosen, MJ; Denson, LA; Minar, P. Journal of Pediatric Gastroenterology and Nutrition. 2019; 69:68-74.

Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients. Clarkston, K; Tsai, Y; Jackson, K; Rosen, MJ; Denson, LA; Minar, P. Journal of Pediatric Gastroenterology and Nutrition. 2019; 69:68-74.

Challenges in IBD Research: Preclinical Human IBD Mechanisms. Pizarro, TT; Stappenbeck, TS; Rieder, F; Rosen, MJ; Colombel, J; Donowitz, M; Towne, J; Mazmanian, SK; Faith, JJ; Hodin, RA; et al. Inflammatory Bowel Diseases. 2019; 25:S5-S12.

IL-33 Induces Murine Intestinal Goblet Cell Differentiation Indirectly via Innate Lymphoid Cell IL-13 Secretion. Waddell, A; Vallance, JE; Hummel, A; Alenghat, T; Rosen, MJ. Journal of immunology (Baltimore, Md. : 1950). 2019; 202:598-607.

Contemporary Medical Management of Acute Severe Ulcerative Colitis. Whaley, KG; Rosen, MJ. Inflammatory Bowel Diseases. 2019; 25:56-66.

Microbiota-sensitive epigenetic signature predicts inflammation in Crohn's disease. Kelly, D; Kotliar, M; Woo, V; Jagannathan, S; Whitt, J; Moncivaiz, J; Aronow, BJ; Dubinsky, MC; Hyams, JS; Markowitz, JF; et al. JCI insight. 2018; 3.